These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 23324986

  • 1. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H, Klamroth R, Vidovic N, Kriukov AY, Epstein J, Abraham I, Spotts G, Oldenburg J.
    Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
    Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B.
    Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V.
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
    Iorio A, Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L.
    Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
    [Abstract] [Full Text] [Related]

  • 8. Perioperative safety and hemostatic efficacy of Advate® in patients with hemophilia A in a postmarketing surveillance in Japan.
    Nogami K, Takedani H, Shima M, Yoshioka A, Matsushita T, Takamatsu J, Taki M, Fukutake K, Uchikawa H, Takagi H, Arai M, Engl W, Shirahata A.
    Int J Hematol; 2018 Jul; 108(1):22-29. PubMed ID: 29594923
    [Abstract] [Full Text] [Related]

  • 9. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, Lissitchkov T.
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM, RAHF-PFM Clinical Study Group.
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [Abstract] [Full Text] [Related]

  • 13. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
    Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R.
    Haemophilia; 2011 Mar; 17(2):191-5. PubMed ID: 20860578
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
    Chen R, Gultyaev D, Lister J, Han R, Hu N, Malacan J, Solms A, Vashi P, O'Hara J, Hu S.
    BMC Med Res Methodol; 2022 Aug 05; 22(1):215. PubMed ID: 35931967
    [Abstract] [Full Text] [Related]

  • 17. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
    Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY, Prophylaxis Study Group.
    J Thromb Haemost; 2012 Mar 05; 10(3):359-67. PubMed ID: 22212248
    [Abstract] [Full Text] [Related]

  • 18. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S, Núñez R, Poveda JL, Kurnik K, Goldmann G, Andreozzi V, Vandewalle B, Santos S.
    Adv Ther; 2021 Sep 05; 38(9):4872-4884. PubMed ID: 34368918
    [Abstract] [Full Text] [Related]

  • 19. Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.
    Fukutake K, Taki M, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Uchikawa H, Takagi H, Arai M, Engl W, Shirahata A.
    Int J Hematol; 2019 Mar 05; 109(3):336-345. PubMed ID: 30604312
    [Abstract] [Full Text] [Related]

  • 20. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES, Stasyshyn O, Alvarez-Román MT, Osman D, Liesner R, Engl W, Sharkhawy M, Abbuehl BE.
    Haemophilia; 2017 Mar 05; 23(2):238-246. PubMed ID: 27891721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.